195 related articles for article (PubMed ID: 7538001)
21. Interferon gamma is effective for BM purging in a patient with CML.
Becker M; Fabrega S; Belloc F; Rice A; Barbu V; Reiffers J
Bone Marrow Transplant; 1993 Aug; 12(2):155-8. PubMed ID: 8401363
[TBL] [Abstract][Full Text] [Related]
22. Serum-free culture of dendritic cells from patients with chronic myeloid leukemia in vitro and estimation of their cytotoxicity.
Zhao W; Xing P; Wei X; Wang T; Yang D; Li M
Chin Med J (Engl); 2002 Sep; 115(9):1296-300. PubMed ID: 12411098
[TBL] [Abstract][Full Text] [Related]
23. A novel triple purge strategy for eliminating chronic myelogenous leukemia (CML) cells from autografts.
Yang H; Eaves C; de Lima M; Lee MS; Champlin RE; McMannis JD; Robinson SN; Niu T; Decker WK; Xing D; Ng J; Li S; Yao X; Eaves AC; Jones R; Andersson BS; Shpall EJ
Bone Marrow Transplant; 2006 Mar; 37(6):575-82. PubMed ID: 16435011
[TBL] [Abstract][Full Text] [Related]
24. Enhanced elimination of Ph+ chromosome cells in vitro by combined hyperthermia and other drugs (AZT, IFN-alpha, TNF, and quercetin): its application to autologous bone marrow transplantation for CML.
Osman Y; Moriyama Y; Shibata A
Exp Hematol; 1995 May; 23(5):444-52. PubMed ID: 7720816
[TBL] [Abstract][Full Text] [Related]
25. Autologous bone marrow transplantation for leukemia.
Stuart RK
Semin Oncol; 1993 Oct; 20(5 Suppl 6):40-54. PubMed ID: 8211215
[TBL] [Abstract][Full Text] [Related]
26. Eilatin: a novel marine alkaloid inhibits in vitro proliferation of progenitor cells in chronic myeloid leukemia patients.
Einat M; Lishner M; Amiel A; Nagler A; Yarkorli S; Rudi A; Kashman Y; Markel D; Fabian I
Exp Hematol; 1995 Dec; 23(14):1439-44. PubMed ID: 8542929
[TBL] [Abstract][Full Text] [Related]
27. Preferential sequestration in vitro of BCR/ABL negative hematopoietic progenitor cells among cytokine nonresponsive CML marrow CD34+ cells.
Veena P; Cornetta K; Davidson A; Agüero B; McMahel J; Traycoff CM; Srour EF
Bone Marrow Transplant; 1997 Jun; 19(12):1213-21. PubMed ID: 9208115
[TBL] [Abstract][Full Text] [Related]
28. Chronic myelogenous leukemia: in search of the benign hematopoietic stem cell.
McGlave P; Verfaillie C; Miller J
Stem Cells; 1993 Oct; 11 Suppl 3():10-3. PubMed ID: 7905318
[TBL] [Abstract][Full Text] [Related]
29. [Autologous bone marrow transplantation for CML].
Nagamura F; Nagamura-Inoue T
Nihon Rinsho; 2001 Dec; 59(12):2369-74. PubMed ID: 11766341
[TBL] [Abstract][Full Text] [Related]
30. 5-Fluorouracil-resistant CD34+ cell population from peripheral blood of CML patients contains BCR-ABL-negative progenitor cells.
Jazwiec B; Mahon FX; Pigneux A; Pigeonnier V; Reiffers J
Exp Hematol; 1995 Dec; 23(14):1509-14. PubMed ID: 8542939
[TBL] [Abstract][Full Text] [Related]
31. BCR/ABL-negative clonogenic hematopoietic cells do not accumulate in the plastic-adherent fraction of peripheral blood mononuclear cells from patients with chronic myeloid leukemia in stable chronic phase.
Schultheis B; Pasternak G; Hehlmann R
Folia Biol (Praha); 2000; 46(6):256-63. PubMed ID: 11140859
[TBL] [Abstract][Full Text] [Related]
32. A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood.
Klingemann HG; Wong E; Maki G
Biol Blood Marrow Transplant; 1996 May; 2(2):68-75. PubMed ID: 9118301
[TBL] [Abstract][Full Text] [Related]
33. Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization.
Mendoza-Maldonado R; Zentilin L; Fanin R; Giacca M
Cancer Gene Ther; 2002 Jan; 9(1):71-86. PubMed ID: 11916246
[TBL] [Abstract][Full Text] [Related]
34. Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells.
Schmidt-Wolf IG; Lefterova P; Johnston V; Scheffold C; Csipai M; Mehta BA; Tsuruo T; Huhn D; Negrin RS
Cell Immunol; 1996 Apr; 169(1):85-90. PubMed ID: 8612299
[TBL] [Abstract][Full Text] [Related]
35. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
[TBL] [Abstract][Full Text] [Related]
36. Autologous BMT in high risk patients with CALLA-positive ALL: possible efficacy of ex vivo marrow leukemia cell purging with monoclonal antibodies and complement.
Morishima Y; Miyamura K; Kojima S; Ueda R; Morishita Y; Sao H; Tanimoto M; Ohno R; Sobue R; Hirano M
Bone Marrow Transplant; 1993 Apr; 11(4):255-9. PubMed ID: 7683550
[TBL] [Abstract][Full Text] [Related]
37. Potent antileukemic activity of the novel agents norsegoline and dibezine.
Einat M; Nagler A; Lishner M; Amiel A; Yarkoni S; Rudi A; Gellerman G; Kashman Y; Fabian I
Clin Cancer Res; 1995 Aug; 1(8):823-9. PubMed ID: 9816051
[TBL] [Abstract][Full Text] [Related]
38. Chronic myelogenous leukemia and acute promyelocytic leukemia: new bone marrow transplantation options.
Viele CS
Oncol Nurs Forum; 1996 Apr; 23(3):488-93. PubMed ID: 8801509
[TBL] [Abstract][Full Text] [Related]
39. Induction of in vitro graft-versus-leukemia activity following bone marrow transplantation for chronic myeloid leukemia.
Mackinnon S; Hows JM; Goldman JM
Blood; 1990 Nov; 76(10):2037-45. PubMed ID: 2242425
[TBL] [Abstract][Full Text] [Related]
40. Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture.
Cervantes F; Pierson BA; McGlave PB; Verfaillie CM; Miller JS
Blood; 1996 Mar; 87(6):2476-85. PubMed ID: 8630414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]